

Provider Bulletin May 2021

Provider manual — Shingles vaccine benefit

This communication applies to the Medicaid programs for Simply Healthcare Plans, Inc. (Simply) and Clear Health Alliance (CHA).

In July 2020, Merck discontinued the sale of Zostavax (live one-dose zoster vaccine) in the United States. The latest expiration date of remaining doses was November 2020. The Advisory Committee on Immunization Practices now recommends recombinant zoster vaccine Shingrix as the preferred shingles vaccine. Shingrix requires two doses and is the only shingles vaccine currently on the market in the United States. If patients had Zostavax in the past, they should still get Shingrix.

Please note that the current provider manual does not reflect this update. This update can be found below on the corresponding page.

Page 36:

Service	Coverage limitations	Prior authorization
Vaccine — Shingles (Shingrix)	For members 50 years of age and	Not required
 Recombinant zoster vaccine 	older; two doses separated by 2 to	
 Subcutaneous/medicine- 	6 months	
immunization administration		